Lipid-lowering therapy in HIV-infected patients: Relationship with antiretroviral agents and impact of substance-related disorders

Cindy Bednasz, Amneris E. Luque, Barry S. Zingman, Margaret A. Fischl, Barbara M. Gripshover, Charles S. Venuto, Jie Gu, Zekun Feng, Robin DiFrancesco, Gene D. Morse, Qing Ma

Research output: Contribution to journalArticle

4 Scopus citations


Background: The use of combination antiretroviral therapy (cART) has significantly decreased the morbidity and mortality associated with human immunodeficiency virus (HIV) infection. Lipid disorders, including lipodystrophy, hypertriglyceridemia, and hypercholesterolemia, remain the most commonly reported metabolic disorders among those treated with long-term cART. Mounting evidence suggests an association between drug abuse and poor glycemic control and diabetes complications. Substance related disorders (SRD) may increase the risk of metabolic syndrome. Materials and Methods: The aim of this retrospective cohort study was to examine the relationship between SRD, cART, and lipid-lowering agent use in an HIV infected population. Patients received efavirenz or protease inhibitor-based cART for at least 6 months. Prescription information was retrieved from the medical records. The primary outcome was the use of lipid-lowering agents including statins, fibrates and fish oil. The impact of SRD and cART was assessed on the lipidlowering agent use. Results: A total of 276 subjects with HIV infection were included, 90 (33%) received lipid-lowering agents, and 31 (34%) had SRD. Smoking was prevalent among subjects with SRD (84 vs 15%, p

Original languageEnglish (US)
Pages (from-to)280-287
Number of pages8
JournalCurrent Vascular Pharmacology
Issue number3
Publication statusPublished - May 1 2016



  • Dyslipidemia
  • Fibrates
  • HIV
  • Lipid-lowering therapy
  • Metabolic disorder
  • Statins
  • Substance-related disorders

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this